The Global Cardiovascular Drugs Market is estimated to be USD 78.96 Bn in 2021 and is expected to reach USD 96.99 Bn by 2026, growing at a CAGR of 4.2%.
However, stringent government regulations associated with the research and development of drugs and the patent expiry of various blockbuster drugs are hindering market growth.
By Drug Type, the market is classified into Antihyperlipidemic, Antihypertensives, Anticoagulants, Antiarrhythmics, and Others. Amongst all, the Anticoagulants segment is estimated to hold the highest market share during the forecast period.
By Disease Indications, the market is classified as Hypertension, Hyperlipidemia, Coronary Artery Disease, Arrhythmia, and Others. Amongst all, the Hypertension segment is estimated to hold the highest market share during the forecast period.
By Route of Administration, the market is classified as Oral, Parenteral, and Others. Amongst all, the Parenteral segment is estimated to hold the highest market share during the forecast period.
By Mode of Purchase, the market is classified as Prescription-Based Drugs and Over-The-Counter Drugs. Amongst the two, the Prescription-Based Drugs segment is estimated to hold the highest market share during the forecast period.
By Drugs, the market is classified as Branded Drugs and Generic Drugs. Amongst all, the Prescription-Based Drugs segment is estimated to hold the highest market share during the forecast period.
By Distribution Channel, the market is classified as Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others. Amongst all, the Hospital Pharmacies segment is estimated to hold the highest market share during the forecast period.
By Geography, North America is projected to lead the market.
2. Bristol Myers Squibb acquired MyoKardia for $13. 1 Bn. Through the transaction, Bristol Myers Squibb gains Mavacamten, a potential cardiovascular medicine for the treatment of obstructive hypertrophic cardiomyopathy (“HCM”) - 10th May 2020
Market Dynamics
According to WHO, around 17.9 million people died from cardiovascular diseases in 2019. Cardiovascular diseases are rising owing to increasingly sedentary lifestyles and unhealthy diets. Additionally, the rising geriatric population has further increased the incidences of cardiovascular diseases, globally. The increasing prevalence of cardiovascular diseases is majorly driving the market growth. The key players are developing new novel drugs for cardiovascular diseases to meet the unmet needs is anticipated to create new opportunities for the market.However, stringent government regulations associated with the research and development of drugs and the patent expiry of various blockbuster drugs are hindering market growth.
Market Segmentation
The Global Cardiovascular Drugs Market is segmented further based on Drug Type, Disease Indications, Distribution Channel, and Geography.By Drug Type, the market is classified into Antihyperlipidemic, Antihypertensives, Anticoagulants, Antiarrhythmics, and Others. Amongst all, the Anticoagulants segment is estimated to hold the highest market share during the forecast period.
By Disease Indications, the market is classified as Hypertension, Hyperlipidemia, Coronary Artery Disease, Arrhythmia, and Others. Amongst all, the Hypertension segment is estimated to hold the highest market share during the forecast period.
By Route of Administration, the market is classified as Oral, Parenteral, and Others. Amongst all, the Parenteral segment is estimated to hold the highest market share during the forecast period.
By Mode of Purchase, the market is classified as Prescription-Based Drugs and Over-The-Counter Drugs. Amongst the two, the Prescription-Based Drugs segment is estimated to hold the highest market share during the forecast period.
By Drugs, the market is classified as Branded Drugs and Generic Drugs. Amongst all, the Prescription-Based Drugs segment is estimated to hold the highest market share during the forecast period.
By Distribution Channel, the market is classified as Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others. Amongst all, the Hospital Pharmacies segment is estimated to hold the highest market share during the forecast period.
By Geography, North America is projected to lead the market.
Recent Developments
1. Merck receives FDA approval for VERQUVO, the First Soluble Guanylate Cyclase Stimulator to Treat Heart Failure. - 20th January 20212. Bristol Myers Squibb acquired MyoKardia for $13. 1 Bn. Through the transaction, Bristol Myers Squibb gains Mavacamten, a potential cardiovascular medicine for the treatment of obstructive hypertrophic cardiomyopathy (“HCM”) - 10th May 2020
Company Profiles
Some of the companies covered in this report are Bristol Myers Squibb Company, Pfizer, Novartis AG, and Abbott Laboratories, etc.Competitive Quadrant
The report includes Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.Why buy this report?
- The report offers a comprehensive evaluation of the Global Cardiovascular Drugs Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.
- The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.
- The report includes an in-depth market analysis using Porter’s 5 forces model and the Ansoff Matrix. In addition, the impact of Covid-19 on the market is also featured in the report.
- The report also includes the regulatory scenario in the industry, which will help you make a well-informed decision. The report discusses major regulatory bodies and major rules and regulations imposed on this sector across various geographies.
- The report also contains the competitive analysis using Positioning Quadrants, the analyst’s Proprietary competitive positioning tool.
Report Highlights:
- A complete analysis of the market, including parent industry
- Important market dynamics and trends
- Market segmentation
- Historical, current, and projected size of the market based on value and volume
- Market shares and strategies of key players
- Recommendations to companies for strengthening their foothold in the market
Frequently Asked Questions about the Global Cardiovascular Drugs Market
What is the estimated value of the Global Cardiovascular Drugs Market?
What is the growth rate of the Global Cardiovascular Drugs Market?
What is the forecasted size of the Global Cardiovascular Drugs Market?
Who are the key companies in the Global Cardiovascular Drugs Market?
Report Attribute | Details |
---|---|
No. of Pages | 189 |
Published | June 2021 |
Forecast Period | 2021 - 2026 |
Estimated Market Value ( USD
| USD 78960 Million |
Forecasted Market Value ( USD
| USD 96990 Million |
Compound Annual Growth Rate | 4.2% |
Regions Covered | Global |
No. of Companies Mentioned | 26 |
Table of Contents
1 Report Description
2 Research Methodology
3 Executive Summary
4 Market Influencers
5 Market Analysis
6 Global Cardiovascular Drugs Market, By Type
7 Global Cardiovascular Drugs Market, By Disease Indications
8 Global Cardiovascular Drugs Market, By Route of Administration
9 Global Cardiovascular Drugs Market, By Mode of Purchase
10 Global Cardiovascular Drugs Market, By Drugs
11 Global Cardiovascular Drugs Market, By Distribution Channel
12 Global Cardiovascular Drugs Market, By Geography
13 Competitive Landscape
14 Company Profiles
15 Appendix
Companies Mentioned
- Abbott Laboratories
- Astellas Pharma, Inc.
- AstraZeneca plc
- Amgen Inc
- Aurobindo Pharma Ltd
- Bayer AG
- Baxter International Inc
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Company
- Cipla Ltd
- Daiichi Sankyo Company Limited
- Eli Lilly and Company
- F.Hoffman-La Roche Ltd
- Gilead Science, Inc
- GlaxoSmithKline plc
- Johnson & Johnson
- Lupin Ltd
- Merck & Co Inc
- Medicure Inc
- Novartis AG
- Otsuka Pharmaceutical
- Pfizer Inc
- Sanofi S.A.
- Sun Pharmaceutical Industries Ltd
- Tadeka Pharmaceutical Company Limited
- United Therapeutics Corporation